A metaregression analysis indicated that , after adjusting for possible confounders , studies where fluoxetine was the experimental agent were positively associated with treatment effect , indicating a significant advantage for fluoxetine .
The evidence that the outcome of fluoxetine trials varied according to whether this drug was used as a new compound or a reference one suggests the presence of bias
The present study investigated whether the outcome of r and omized clinical trials study ing fluoxetine favored fluoxetine , where this was the experimental agent , and favored comparator antidepressants in trials where fluoxetine was the reference agent .
Fluoxetine versus phenelzine in atypical depression
A study was conducted to compare the relative efficacy of fluoxetine and phenelzine in patients with mood-reactive atypical depression . Forty-two patients with atypical depression by the Columbia criteria were studied in a r and omized , double-blind treatment study . Following a single-blind placebo lead-in , patients received fluoxetine 20 - 60 mg/day or phenelzine 45 - 90 mg/day for 6 weeks . Efficacy was measured by the Hamilton Depression Rating Scale , the Clinical Global Impression ( Severity and Improvement ) scales , and the Patient Global Impression ( Improvement ) scale .  Of 42 patients r and omized , 2 patients never received drugs and 2 phenelzine-treated patients dropped out prior to completion ; the remainder completed the 6 weeks of the study . The rates of treatment response did not differ between groups . With a few exceptions ( e.g. , tremor ) , phenelzine produced more frequent adverse effects than fluoxetine . It was concluded that fluoxetine is as effective as phenelzine in the treatment of atypical depression , but produces fewer adverse effects and is better tolerated
A metaregression analysis indicated that , after adjusting for possible confounders , studies where fluoxetine was the experimental agent were positively associated with treatment effect , indicating a significant advantage for fluoxetine .
The evidence that the outcome of fluoxetine trials varied according to whether this drug was used as a new compound or a reference one suggests the presence of bias
The present study investigated whether the outcome of r and omized clinical trials study ing fluoxetine favored fluoxetine , where this was the experimental agent , and favored comparator antidepressants in trials where fluoxetine was the reference agent .